Kathrin Tholen1, Falk Hoffmann. 1. Department for Health Economics, Health Policy and Outcome Research, Centre for Social Policy Research, University of Bremen, Bremen, Germany. ktholen@zes.uni-bremen.de
Abstract
PURPOSE: Tramadol is a weak opioid according to the World Health Organization pain ladder step II. It is one of the most prescribed analgesic substances in Germany, but tramadol and the step II opioids are very controversially discussed. We analysed patients with filled tramadol prescriptions with special emphasis on high use. METHODS: We used data from a German statutory health insurance for the year 2007. Patients older than 17 years with at least one tramadol prescription were analysed concerning demographic data, pain diagnoses, comorbidities, concomitant opioids, physician contacts and number of different prescribed substances. We fitted a logistic regression model to find relevant associations with high use (defined as >180 daily defined doses per year). RESULTS: From 22 ,946 insurants with filled tramadol prescriptions, 7.9% (n = 1812) are identified as high users; 90.9% of all tramadol patients and 93.1% of the high users have at least one pain diagnosis. The most frequent diagnoses are back pain (78.4% vs 77.1%) and arthritis pain (37.9% vs 41.8%). The results of the logistic regression model show associations between high use of tramadol and rising age, unspecific pain diagnoses, psychiatric co-morbidities, additional prescribed strong opioids and a high number of physician contacts. CONCLUSIONS: Despite some limitations, this study shows the prescriptions of tramadol in Germany in an authentic way. It seems that there are some 'challenging' patients that present a treatment dilemma for some prescribers. This might result in a high use of tramadol.
PURPOSE:Tramadol is a weak opioid according to the World Health Organization pain ladder step II. It is one of the most prescribed analgesic substances in Germany, but tramadol and the step II opioids are very controversially discussed. We analysed patients with filled tramadol prescriptions with special emphasis on high use. METHODS: We used data from a German statutory health insurance for the year 2007. Patients older than 17 years with at least one tramadol prescription were analysed concerning demographic data, pain diagnoses, comorbidities, concomitant opioids, physician contacts and number of different prescribed substances. We fitted a logistic regression model to find relevant associations with high use (defined as >180 daily defined doses per year). RESULTS: From 22 ,946 insurants with filled tramadol prescriptions, 7.9% (n = 1812) are identified as high users; 90.9% of all tramadolpatients and 93.1% of the high users have at least one pain diagnosis. The most frequent diagnoses are back pain (78.4% vs 77.1%) and arthritis pain (37.9% vs 41.8%). The results of the logistic regression model show associations between high use of tramadol and rising age, unspecific pain diagnoses, psychiatric co-morbidities, additional prescribed strong opioids and a high number of physician contacts. CONCLUSIONS: Despite some limitations, this study shows the prescriptions of tramadol in Germany in an authentic way. It seems that there are some 'challenging' patients that present a treatment dilemma for some prescribers. This might result in a high use of tramadol.
Authors: Thi Ngoc Mai Nguyen; Dana Clarissa Laetsch; Li-Ju Chen; Walter Emil Haefeli; Andreas D Meid; Hermann Brenner; Ben Schöttker Journal: Eur J Clin Pharmacol Date: 2020-07-10 Impact factor: 2.953
Authors: Sahan Jayawardana; Rebecca Forman; Charlotte Johnston-Webber; Allen Campbell; Stefano Berterame; Cees de Joncheere; Murray Aitken; Elias Mossialos Journal: EClinicalMedicine Date: 2021-11-13
Authors: Shirley Musich; Shaohung S Wang; James A Schaeffer; Luke Slindee; Sandra Kraemer; Charlotte S Yeh Journal: Popul Health Manag Date: 2020-03-02 Impact factor: 2.459
Authors: Che Suraya Zin; Nor Ilyani Nazar; Norny Syafinaz Rahman; Nor Elina Alias; Wan Rohaidah Ahmad; Nurul Sahida Rani; Mary Suma Cardosa; Kim Swan Ng; Felicia Loh Ye Journal: J Pain Res Date: 2018-09-20 Impact factor: 3.133